Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026
MWN-AI** Summary
Evogene Ltd. (NASDAQ: EVGN), a leader in computational chemistry, is set to showcase its pharmaceutical discovery advancements at the upcoming BIO-Europe Spring 2026 conference in Lisbon, Portugal, scheduled for March 23-25, 2026. Representing the company, Dr. Gabi Tarcic, Chief Development Officer, and Dr. Olga Nissan, VP of Business Development, will highlight the innovative achievements of Evogene’s pharma division during the event.
A focal point of Evogene's presentation will be the company's breakthrough technology, ChemPass AI™, which employs generative artificial intelligence to design highly potent small molecules for both the pharmaceutical and agricultural sectors. Dr. Nissan will deliver an oral presentation emphasizing how ChemPass AI™ facilitates collaborative drug discovery efforts with pharmaceutical and biotech partners by optimizing the search across an extensive chemical space.
The presentation, titled "Drug Discovery and Development: Evogene," is scheduled for March 24, 2026, from 15:30 to 15:45 WET at Theatre A. Alongside the presentation, both Dr. Tarcic and Dr. Nissan will be available for one-on-one meetings, encouraging interested parties to connect with Evogene’s investor or public relations team.
Evogene's strategic focus on merging AI-driven molecular design with experimental validation aims to enhance the success rates of new drug candidates. The company emphasizes creating innovative products aligning with real-world industry requirements, underscoring its commitment to fostering scientific advancement in the drug discovery landscape.
Investors and interested stakeholders can learn more by visiting Evogene’s official website. The company’s forward-looking statements indicate optimism around its ongoing developments, while also recognizing the potential risks and uncertainties inherent in the pharmaceutical and biotechnology sectors.
MWN-AI** Analysis
Evogene Ltd. (NASDAQ: EVGN) is poised to leverage its participation in the upcoming BIO-Europe Spring 2026 conference to enhance market visibility and stakeholder engagement regarding its pharmaceutical division. The company’s focus on AI-driven small-molecule discovery through its proprietary platform, ChemPass AI™, positions it uniquely within the competitive landscape.
As Evogene prepares to unveil advancements in drug discovery, investors should closely monitor the outcomes and insights shared by Dr. Gabi Tarcic and Dr. Olga Nissan during the presentation. Their discussion will likely highlight the potential of ChemPass AI™ to catalyze collaborative ventures with pharmaceutical and biotech partners, which may significantly impact Evogene's future revenue streams and partnerships.
Historically, Evogene has demonstrated a strong commitment to innovation in computational chemistry, asserting its potential to address unmet medical needs through groundbreaking product development. Investors should consider how the presentation may serve as a litmus test for the broader viability of its technology and its ability to attract further investments or partnerships.
Further, given the inherent risks associated with conducting drug discovery in a volatile geopolitical landscape, particularly following recent conflicts in the region, market participants should weigh these factors against the company's collaborative framework and its strategic partnerships, which could mitigate operational risks.
Overall, Evogene’s forthcoming presentation at the BIO-Europe Spring serves as a critical inflection point that could impact its market perception and stock performance. Investors are advised to maintain a close watch on developments from the conference to better inform their positions. The potential for technological breakthroughs combined with a proactive business development approach could present favorable investment opportunities in the evolving biotech sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Conference will be held at Lisbon, Portugal - March 23–25, 2026
REHOVOT, Israel, March 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced it will be featured as a presenting company at the upcoming BIO-Europe Spring 2026 conference, being held on March 23-25, in Lisbon. Attending the conference on behalf of Evogene will be Dr. Gabi Tarcic, Chief Development Officer and Dr. Olga Nissan, VP Business Development.
At the conference, Evogene will present the latest achievements of its pharma division. Dr. Nissan will deliver an oral presentation highlighting the company's technological breakthroughs in AI-driven small-molecule discovery and optimization and will share insights into how ChemPass AI™ is enabling new opportunities for collaborative drug discovery with pharmaceutical and biotech partners.
Presentation Details:
Drug Discovery and Development: Evogene
Tuesday, March 24, 2026 | 15:30–15:45 WET | Theatre A
Dr. Tarcic and Dr. Nissan will both be available for one-on-one meetings at the conference, interested parties are encouraged to contact Evogene's investor or public relations team.
To register as a participant of the conference see:
https://informaconnect.com/bioeurope-spring/
About Evogene Ltd.:
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries.
At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. By integrating AI-driven molecular design with experimental validation, ChemPass AI™ enables the efficient discovery of differentiated small-molecule candidates with improved probability of development success. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.
For more information, please visit www.evogene.com.
Forward-Looking Statements:
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene and its subsidiaries use forward-looking statements in this press release when they discuss: Evogene's achievements of its pharma division, Evogene's technological breakthroughs in AI-driven small-molecule discovery and optimization, and the potential of ChemPass AI™ to enable new opportunities for collaborative drug discovery with pharmaceutical and biotech partners. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the aftermath of the recent war between Israel and each of (i) the terrorist groups, Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any potential destabilizations in Israel, neighboring territories or the Middle East region, and those risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Contact
ir@evogene.com
Tel: +972-8-9311901
Logo: https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg
SOURCE Evogene
FAQ**
What specific AI-driven breakthroughs in small-molecule discovery will Evogene Ltd. EVGN highlight during its presentation at BIO-Europe Spring 2026, and how do these advancements position the company competitively in the pharmaceutical industry?
How does Evogene Ltd. EVGN's ChemPass AI™ enhance the efficiency and success probability of drug discovery, and what collaborative opportunities does it create for partnerships with other pharmaceutical and biotech companies?
Can you elaborate on how Evogene Ltd. EVGN integrates its generative AI technology with experimental validation and what impact this integration has on the development timeline for new drug candidates?
Considering the potential risks mentioned in the press release, how is Evogene Ltd. EVGN managing the challenges presented by geopolitical instability, particularly in relation to its ongoing drug discovery initiatives and partnerships?
**MWN-AI FAQ is based on asking OpenAI questions about Evogene Ltd. (NASDAQ: EVGN).
NASDAQ: EVGN
EVGN Trading
2.28% G/L:
$0.8377 Last:
171,157 Volume:
$0.8133 Open:
